These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
617 related articles for article (PubMed ID: 28474297)
21. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286 [TBL] [Abstract][Full Text] [Related]
22. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551 [TBL] [Abstract][Full Text] [Related]
23. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Rimel BJ; Dockery L; Randall LM; Moore K Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196 [TBL] [Abstract][Full Text] [Related]
24. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000 [TBL] [Abstract][Full Text] [Related]
25. Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study. Aoki D; Tabata T; Yanagida S; Nakamura T; Kondo E; Hamanishi J; Harano K; Hasegawa K; Hirasawa T; Hori K; Komiyama S; Matsuura M; Nakai H; Nakamura H; Sakata J; Takehara K; Takekuma M; Yokoyama Y; Kase Y; Sumino S; Soeda J; Kato A; Suri A; Okamoto A; Sugiyama T J Gynecol Oncol; 2024 Sep; 35(5):e114. PubMed ID: 39251349 [TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820 [TBL] [Abstract][Full Text] [Related]
27. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Onstad M; Coleman RL; Westin SN Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746 [TBL] [Abstract][Full Text] [Related]
28. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175 [TBL] [Abstract][Full Text] [Related]
29. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group. Musacchio L; Palluzzi E; Di Napoli M; Lauria R; Ferrandina G; Angioli R; Bergamini A; Corrado G; Perniola G; Cassani C; Savarese A; Gori S; Greco F; De Angelis C; Zafarana E; Giannarelli D; Cinieri S; Mosconi AM; Raspagliesi F; Pignata S; Scambia G; Lorusso D Gynecol Oncol; 2024 May; 184():24-30. PubMed ID: 38277918 [TBL] [Abstract][Full Text] [Related]
30. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]
31. Niraparib Slows Ovarian Cancer Progression. Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860 [TBL] [Abstract][Full Text] [Related]
33. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391 [TBL] [Abstract][Full Text] [Related]